Drug Digest: Keeping Pace with Progressive Technologies in Biopharma Development

Published on: 

This episode of Drug Digest will discuss where the significant bottlenecks are in the development and manufacturing of new molecules resulting from progressive technologies, such as AI and ML, and how best to approach these challenges.

Advertisement

The biopharma industry is at a time where progressive technologies such as artificial intelligence, machine learning, and digitalization technologies are making a significant impact on how drug discovery, development, and manufacturing are being driven. Yet the question remains as to how the industry itself is keeping up with the fast-paced innovation churning out from these advanced technologies. This episode of Drug Digest will examine where the significant bottlenecks are in the development and manufacturing of new molecules resulting from these progressive technologies, and how best to approach these challenges.

Interview featuring

  • Kevin Dondarski, Principal, Life Sciences R&D, Deloitte Consulting
  • Maryland Franklin, PhD, Vice-President and Enterprise Head, Cell and Gene Therapy, Labcorp
  • Lidia Serina, PhD, head of Development Services at Simtra BioPharma Solutions
  • Sean Tucker, PhD, Founder and Chief Scientific Officer, Vaxart

Sponsors

This episode of Drug Digest is sponsored by:

  • Biovectra
  • Eppendorf
  • Kindeva
  • Veltek

About Drug Digest

Drug Digest is a tech talk video series with the Pharmaceutical Technology® editors, who interview industry experts to discuss the emerging opportunities, obstacles, and advances in the pharmaceutical and biopharmaceutical industry for the research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging of drug products.

Upcoming episodes

  • May/June 2025: Solid Dosage Formulation Trends
  • July/August 2025: Large-Molecule Manufacturing Trends
  • September 2025: Developments in Small-Molecule APIs, Excipients, and Ingredients